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Human immunodeficiency virus (HIV) type 1 dysregulates γδT cells as part of an immune
evasion mechanism. Nearly three decades of research defined the effects of HIV on γδ T
cells and how this impacts disease. With highly effective antiretroviral therapy providing
virus suppression and longer survival, we expected a return to normal for γδ T cells. This
is not the case. Even in patients with CD4 T cell reconstitution, normal γδT cell levels and
function are not recovered.The durable damage to Vδ2T cells is paralleled by defects in NK,
CD8 T cells, and dendritic cells. Whether these consequences of HIV stem from similar or
distinct mechanisms are not known and effective means for recovering the full range of
cellular immunity have not been discovered.These unanswered questions receive too little
attention in the overall program of efforts to cure HIV this disease. Approved drugs capable
of increasingVδ2T cell function are being tested in clinical trials for cancer and hold promise
for restoring normal function in patients with HIV disease.The impetus for conducting clin-
ical trials will come from understanding the significance of γδ T cells in HIV disease and
what might be gained from targeted immunotherapy. This review traces the history and
current progress of AIDS-related research on γδT cells. We emphasize the damage to γδT
cells that persists despite effective virus suppression. These chronic immune deficits may
be linked to the comorbidities of AIDS (cancer, cardiovascular disease, metabolic disease,
and others) and will hinder efforts to eradicate HIV by cytotoxic T or NK cell killing. Here,
we focus on one subset of T cells that may be critical in the pathogenesis of HIV and an
attractive target for new immune-based therapies.
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ORIGINAL STUDIES ON HIV AND γδ T CELLS
Human immunodeficiency virus (HIV) is an aggressive, lym-
photropic virus known for CD4 depletion and immune suppres-
sion. In addition to killing CD4 T cells, HIV affects several other
lymphocyte subsets (1) and impairs both acquired and innate
immunity (2). We focus on HIV damage to γδ T cells and how
this is related to acute or chronic disease. The two major subsets
of human γδ T cells (designated Vδ1 or Vδ2) are both altered
after HIV infection. Early reports that Vδ1 T cells were increased
(3) and that the normal ratio of Vδ2:Vδ1 cells was inverted (4)
identified an important and reproducible effect of HIV on these
CD4-negative T cells. The increased levels of Vδ1 cells suggested
they may be involved in antiviral immunity (5) and parallels were
drawn between the expansion of Vδ1 cells and similar increases
in CD8+ T cells (5) that contribute to the inverted CD4:CD8
T cell ratio (6). Non-human primate studies showed that Vδ1 cell
expansion is an indirect consequence of viral infection and reflects
increased translocation of stimulatory bacterial products across
the gut epithelium (7). The Vδ1 cells may have antiviral functions
through killing of infected cells using the NKp30 (8) or NKG2C
recognition receptors (9). Killing of uninfected CD4 T cells by Vδ1
cells may also be a mechanism for HIV disease (10). Whether Vδ1
T cells accelerate or slow HIV progression has not been resolved.
In contrast to Vδ1 cells, the Vδ2 subset is uniformly depleted in
HIV disease with the greatest declines seen among patients with
high viremia (11). These early studies [before the introduction of
combination antiretroviral therapy (ART)] involved patients who
were untreated or received single drug therapy where viremia was
reduced 10–50-fold but never suppressed fully. The lowest levels of
Vδ2 cells were found in patients with opportunistic infections or
CD4 T cells< 200 cell/mm3 of blood (12, 13). These individuals
frequently had no detectable cells bearing the phosphoantigen-
responsive Vγ9 chain (14). Importantly, decreases in Vδ2 cells and
inversion of the Vδ2:Vδ1 cell ratio were early events in HIV dis-
ease that occurred while CD4 cell counts and their CD4:CD8 T
cell ratio were still in the normal ranges.
Molecular analysis of γ and δ T cell receptor (TCR) chain usage
showed that HIV-driven expansion of Vδ1 cells did not select for
specific Vδ chain rearrangements or individual Vγ chains (15).
Sequencing studies to describe the TCR repertoire confirmed that
the population of Vδ1 chains was similar in donors with or with-
out HIV infection and that HIV-driven Vδ1 cell expansion was
not similar to antigen selection in αβ T cells (16) but more likely
was a polyclonal or super-antigen response. In contrast to the
case for Vδ1 cells, there was strong evidence for selective Vδ2 cell
depletion based on TCR structure. Flow cytometry studies docu-
mented the specific loss of Vγ9 (also called Vγ2) expressing cells,
a chain more frequently associated with Vδ2 than Vδ1 in healthy
controls. Finding that the relative proportion of Vγ9 expressing
cells was decreased in HIV patients, being lower in both blood
and bronchoalveolar lavage specimens despite having increased
Vδ1 cells (17), encouraged a closer look at the Vγ9Vδ2 subset.
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The importance of Vγ9Vδ2 T cell depletion and the relationship
between depletion and TCR became more clear as other groups
defined antigens for these unusual cells.
FINDING THE ANTIGENS FOR Vδ2 T CELLS
Major activities of Vγ9Vδ2 T cells include a strong response to
Mycobacterium-infected human PBMC, even though these cells
do not react to purified mycobacterial 65-kd heat shock protein
(18). The Vγ9Vδ2 T cells respond to Mycobacteria-pulsed cells
or antigens found on the human MOLT-4 lymphoma cell line
(19), which was confusing in the context of the model for MHC-
restriction that explainedαβT cell recognition of peptide antigens.
Recognition of either Mycobacterium-pulsed cells or lymphoma
cell lines required a specific rearrangement between the variable
γ9 (Vγ9) and joining P (JP) segments; constant region 1 (C1)
was incorporated by mRNA splicing to form Vγ9JPC1 chains that
combine with a Vδ2DJC chains to form functional receptors (20,
21). In an alternate nomenclature, the V-J rearrangement is des-
ignated Vγ2Jγ1.2; the nomenclature is consistent for δ chains.
This combination of specifically rearranged Vγ9 with Vδ2 chains
endowed the capacity for recognizing mycobacterial antigens (22,
23). Efforts to characterize stimulatory molecules showed first
they were phosphorylated (24) and later that they were prenyl
pyrophosphate intermediates of sterol synthesis in mammalian
cells (25). A variety of natural and non-natural molecules were
tested for Vγ9Vδ2 T cell stimulation to define the essential anti-
genic structure (26) within a group of chemicals now known as
phosphoantigens. The natural abundance of mammalian phos-
phoantigens, being made in every living cell, in addition to struc-
turally similar but often more potent compounds produced by
bacteria, protists, plants, or fungi, serves to inundate human phys-
iology with stimulators of Vγ9Vδ2 T cells. These compounds
select for and amplify the Vγ9JPVδ2 cell subset during early life
as was described in a remarkable paper from Michael Brenner’s
group (27).
In children, a fetal Vγ9 chain repertoire is replaced slowly
with one dominated by the Vγ9JγP rearrangement. Under con-
tinuous positive selection, the Vγ9Vδ2 cell count rises and
phosphoantigen-responsive cells are increasingly found in blood
as central or effector memory types with declining proportions of
naïve cells. Healthy adults maintain a diverse but highly redun-
dant repertoire such that 1 in 40 circulating memory T cells is a
phosphoantigen-responsive Vγ9Vδ2 T cell. Clearly, the Vγ9JPVδ2
cell dominates T cell memory in healthy adults. Baseline levels of
Vγ9Vδ2 T cells differ by two to fourfold between white European-
origin or Asian-origin (high) and African-origin (low) peoples but
repertoire complexity is similar among these groups and in vitro
responses to phosphoantigen are also similar (28). Positive selec-
tion and amplification of Vγ9JPVδ2 T cells is ubiquitous in man
and present in most non-human primate species studied so far,
but is not present in lower mammals including rodents that lack
both a gamma chain gene similar to Vγ9 and butyrophilin 3A1
that is also required for phosphoantigen responses (29–34).
SPECIFIC DESTRUCTION OF ANTIGEN-SPECIFIC Vδ2 T CELLS
IN HIV DISEASE
Two important papers in 1996 and 1997 helped to bridge HIV
studies with the emerging understanding of phosphoantigens and
their importance to γδ T cell biology. Gougeon’s group confirmed
earlier studies on Vδ2 cell depletion in HIV patients and reported a
disease-associated “functional anergy” measured by lack of prolif-
eration or cytokine responses after stimulation with mycobacterial
antigens (35). These authors studied the junctional diversity of
Vγ9Vδ2 TCR chains expressed in HIV+ individuals and reported
that theVδ2 cell chain repertoire remained diverse. They also noted
there were no differences in spontaneous apoptosis between HIV
patients or uninfected control donors after in vitro phosphoanti-
gen stimulation. A second group led by Malkovsky confirmed the
functional anergy in Vδ2 T cells from HIV patients by document-
ing decreased responses to phosphoantigen or to the prototypical
cell target Daudi B cell (36). Both groups noted that Vδ2 T cells
were reduced but not eliminated in HIV disease, and were substan-
tially deficient in their response to phosphoantigen due to anergy
that may have resulted from inappropriate activation in vivo. A
smaller study of HIV+ individuals noted differences from con-
trols regarding γδ T cell responses to Salmonella typhimurium or
Candida albicans, and reported thatVδ2 cell responses to Mycobac-
teria remained intact only in patients with>500 CD4 T cells/mm3
(37). Further, Vδ2 cells were depleted from blood but increased in
liver from both HIV patients and HIV-negative patients who had
disseminated Mycobacterium avium complex (38). Vδ1 cells were
increased in tissue sites among HIV patients, notably liver (39) or
bone marrow (40). The pattern of changes among γδ T cells for
both Vδ2 and Vδ1 cells was a distinguishing feature of HIV disease.
MILESTONE ACHIEVEMENTS FROM EARLY STUDIES ON γδ T
CELLS IN HIV DISEASE
By 1997, there was a basic understanding of HIV infection and
its impact on γδ T cells. Four major concepts had emerged: (1)
Inversion of the Vδ2:Vδ1 cell ratio was an early event, occurring
prior to inversion of the CD4:CD8 T cell ratio. (2) Vδ1 cells are
increased in patients with HIV. (3) The Vδ2 cell depletion was
accompanied by decreased responsiveness to phosphoantigens or
tumor cells. (4) Loss of Vδ2 cells was greatest in patients with
low CD4+ T cells, high viremia, opportunistic infections and late
stage disease (AIDS). Consequently, HIV-mediated changes in γδ
T cells appear to be part of the mechanism for evading antivi-
ral immunity and establishing persistent infection with chronic
disease. Persistent infection is essential for viruses like HIV that
are transmitted with relatively low efficiency and require direct
person-to-person contact. These studies highlighted the need to
understand mechanisms forγδT cell dysregulation, define impacts
of these changes on immunity to HIV and look more broadly at
“unintended consequences” of the viral immune evasion strategy.
MECHANISMS FOR DYSREGULATING γδ T CELLS
Model studies in non-human primates have helped to explain
some of the γδ T cell changes during disease. Because rodents
lack the TCR sequences needed for phosphoantigen recognition,
studies on Vγ9Vδ2 T cells have been restricted to human beings
and non-human primates. A recent genome mining study revealed
that functional genes for Vγ9Vδ2 and butyrophilin 3A1 were actu-
ally present in a few other placental mammals including alpaca,
sloth, bottlenose dolphin, killer whale, horse, and armadillo (41).
Most of these species are unfamiliar experimental systems with the
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exception of armadillo that has been used for research on Mycobac-
terium leprae, but we can expect humans and non-human primate
models to dominate this field for the foreseeable future.
When peripheral blood Vγ9Vδ2 T cells were isolated from
uninfected rhesus monkeys (naïve to viral antigens) they were
directly cytotoxic for SIV-infected target cells (42). There were
rapid increases in blood Vγ9Vδ2 T cell counts and higher expres-
sion of activation markers within a few days after SIV infection
of rhesus monkeys even though these cells were already showing
decreased proliferation responds in vitro (43). The Vγ9Vδ2 T cell
expansion seen early after SIV infection of macaques was brief
and was followed by a rapid decline in cell count and function.
This animal model recapitulates the decline in Vγ9Vδ2 T cells and
inversion of the Vδ2:Vδ1 cell ratio. Similarly, Vγ9Vδ2 cell lines
or clones from HIV-negative donors recognized and killed HIV-
infected cells (44). It was also known that healthy Vγ9Vδ2 cells
produced large amounts of interferon-γ, tumor necrosis factor-
α, and chemokines RANTES or MIP-1β (45) that were associated
with antiviral immunity. Normally, the circulating Vγ9Vδ2 cells
(mostly memory phenotype) have preformed cytoplasmic vesicles
containing RANTES that are released immediately upon phos-
phoantigen stimulation or after contact with target cells (46).
The release of RANTES and other chemokines suppressed HIV
replication in vitro by blocking co-receptors for virus entry (47,
48). The CCR5 receptor is highly expressed on Vδ2 cells (49)
meaning RANTES release would attract even more Vγ9Vδ2 cells
able to release additional chemokine that would block HIV entry,
kill already infected cells through direct cytotoxicity, or mediate
antibody-dependent cellular cytotoxicity through cell surface Fc
γ receptors (50). Circulating Vγ9Vδ2 cells also activate innate
and acquired immunity through the release of pro-inflammatory
IFN-γ and TNF-α or regulatory cytokines (51).
While it seemed clear that γδ T cell dysregulation is part of HIV
immune evasion, the precise impact on pathogen immunity was
less clear. Little was known about how Vδ1 expansion or Vδ2 T cell
depletion affect normal immunity and whether these are impor-
tant aspects of viral immune suppression linked to progressing
disease. Brenchley’s group (7) reported that Vδ1 cell expansion in
SIV-infected rhesus monkeys was related to pathologic changes
in the intestinal epithelium that increased bacterial translocation
causing higher levels of bacterial products in circulation that would
stimulateVδ1 T cells. TheVδ1 cells were also increased by influenza
vaccination in HIV patients but only if the vaccine contained MF-
59 adjuvant (52). Thus, Vδ1 cells are responsive to stimulation in
HIV patients and expansion could be linked to bacterial transloca-
tion or reflect the normal responses to Candida albicans (53) and
other common intercurrent infections in HIV patients.
Like Vδ1, phosphoantigen-responsive Vδ2 cells increase soon
after infection as was documented in the SIV infection of macaques
(43) but then are depleted and often extinguished. When cloned
Vδ2 T cells are stimulated by anti-CD3 monoclonal antibody plus
IL-2 they frequently die due to apoptosis, yet anti-CD3 stimu-
lation plus feeder cells in the absence of exogenous IL-2 leads
to proliferation (54). Thus, stimulation conditions impact out-
come. It remains difficult to extrapolate in vitro conditions into
explanations for in vivo outcomes and the mechanism for HIV-
mediated depletion are still unclear. Laboratories working with
Vδ2 T cells, including our groups, know that phosphoantigen plus
IL-2 stimulation of human or macaque PBMC results in rapid
cell death followed by outgrowth of a surviving population that
peaks around 10–14 days later. The repertoire of Vγ9JPC1 chains
is essentially unchanged in the expanded subset compared to fresh
cells (55), despite the fact that stimulation indices for individual
clones vary 10–100-fold (56). Surprisingly, there were no signifi-
cant differences in apoptosis after in vitro stimulation comparing
Vδ2 cells from HIV-infected patients or uninfected controls (35)
but the preferential loss of phosphoantigen responses in HIV dis-
ease still argues for a direct link between antigen specificity and
depletion, apparently a different type of activation-induced cell
death.
Gene expression array studies provided a surprising insight
into infection and γδ T cell dysregulation that may impact Vδ2
cells. During HIV infection, mRNA for enzymes in the cholesterol
biosynthesis pathway is upregulated (57, 58). Higher production
of cholesterol is needed to meet the demands for viral membrane
synthesis and more of the biosynthetic intermediates are required
including prenyl pyrophosphates (phosphoantigens). With more
phosphoantigen present, it is reasonable to expect greater activa-
tion of Vγ9Vδ2 T cells and this may explain the rapid decreases
during acute infection when viremia is highest and the frequency
of infected cells is also highest compared to other stages of disease.
We also know (49, 59) that a large proportion of activated γδ
T cells express chemokine receptors including CCR5 and CXCR4
that are major co-receptors for HIV (Figure 1). These receptors
bind sequences in the V3 loop of envelope glycoprotein gp120 and
are important for viral entry. Both Vδ2 and Vδ1 cells express α4β7
integrin that also binds the V2 loop of gp120 (60, 61). CCR5
expression was only seen in the Vδ2 subset where it was esti-
mated to be present at >50,000 molecules per cell surface (62),
or roughly 10-fold higher surface density compared to activated
αβ CD4 T cells. Treating expanded Vδ2 cells with gp120 lead to
induction/activation of caspases followed by apoptosis. Inhibitor
studies confirmed that signaling through CCR5 and its associated
CCR5
alpha4beta7 alpha4beta7
Vδ2 T Cells Vδ1 T Cells
•p38 MAPK ac"va"on
•caspase ac"va"on
•cell death
HIV gp120 or
virus par"cle
DEPLETED EXPANDED
FIGURE 1 | Human immunodeficiency virus envelopes gp120 signaling
through CCR5 is a mechanism for specific depletion of Vδ2T cells. Vδ2 T
cells express high levels of two binding molecules for HIV gp120:
chemokine receptor CCR5 and integrin α4β7. In Vδ1 cells, gp120 (green
trimers) bind to α4β7 (purple polygons) but do not signal caspase activation
or cause cell death. In Vδ2 T cells, the presence of 7-transmembrane CCR5
(red) binds gp120 and signals through its associated p38 MAP kinase to
increase caspase activity and cell death. Adapted from Ref. (62, 63).
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p38 MAP kinase, was necessary for this cell death pathway (62).
We also detected gp120 binding to Vδ1 cells that could be blocked
by ligands for α4β7 but was not affected by the CCR5 antagonistic
drug Maraviroc. Flow cytometry showed that Vδ1 cells have no
detectable surface CCR5 (63). The presence of high density CCR5
on Vδ2 T cells and its absence on Vδ1 T cells may explain spe-
cific cell killing of Vδ2 cells by gp120 that is similar to the pattern
seen during HIV infection. Since high density CCR5 expression
occurs on phosphoantigen-stimulated cells, this mechanism might
account for the connection between antigen specificity and cell
loss.
Several other models have been proposed to explain the γδ T
cell defect in HIV disease. We first reported that Vγ9Vδ2 T cells
activated in vitro were permissive for HIV infection (36) but the
number of productively infected cells in patient samples seems to
be very low. However, it was reported that human herpes virus 6
elevates CD4 on several cell types including γδ T cells (64) and
could impact susceptibility of these cells in vivo. Both direct infec-
tion of intrathymic γδ T cell precursors (65) and inhibition of
thymic development by HIV-infected γδ T cells (66) were pro-
posed as models for specific or general T cell depletion. However,
it is important to note that Vδ1 cells are not depleted during HIV
disease as would be expected for a mechanism acting at the level
of thymopoiesis. In addition, the normal human blood repertoire
includes Vγ9Vδ2 cells that use both the JP and other rearrange-
ments even though we emphasize Vγ9JP because of its responses
to phosphoantigens. Sequencing studies showed that Vγ9Vδ2 cells
using J segments other than JP, remained at normal levels and
appeared to be unchanged during HIV disease (14). Further, the
rapid depletion of Vγ9Vδ2 T cells before the onset of immunod-
eficiency and reactivation of pathogens like HHV-6, argues this
is not a major mechanism for depletion. The impact of direct
infection, despite infrequent CD4 expression or negative effects
on thymopoiesis may contribute to Vγ9Vδ2 cell depletion but are
not likely to be the major mechanisms.
Based on studies of former plasma donors in southern China
who were infected at the same time and with similar strains of
HIV, we know that Vδ2 levels correlate with viremia (hence levels
of gp120) but not with CD4 T cell count (67). This adds support
to a model where viral proteins are directly responsible for Vδ2
cell depletion as was proposed earlier (11). During natural history
studies of HIV disease it will be important to identify patients
being treated with CCR5 antagonists including Maraviroc, who
may have increased Vδ2 T cells compared to patients treated with
regimens that do not include this drug class.
In order to understand better the dynamics of Vδ2 T cell deple-
tion and the potential for immune reconstitution during therapy,
extensive use was made of TCR repertoire analysis (Figure 2).
The focus has been on the Vγ9 chain that is most tightly linked
to phosphoantigen responsiveness due to the predominant Vγ9JP
rearrangement (also called Vγ2Jγ1.2). Indeed, sequencing stud-
ies on the γ chain repertoire established the specificity of HIV-
mediated deletion in the Vδ2 cell population (12) and subsequent
work [reviewed in Ref. (68)] showed this TCR-specific defect is
common to all HIV patients regardless of virus type, geographic
distribution, race, or ethnicity. In the era before effective antiretro-
viral therapy, repertoire sequencing studies showed that patients
Vδ2 PAg-
responsive
Vδ2 unknown 
antigen
Healthy, 
HIV-negative
HIV-positive,
no ART
HIV-positive,
>7 yr ART
FIGURE 2 |The impact of HIV infection on circulating Vγ9Vδ2T cells.
The characteristics of circulating Vγ9Vδ2 T cells (abbreviated Vδ2) are
summarized for healthy, HIV-uninfected, and HIV-infected patients without
antiretroviral therapy (ART) or after >7 years of ART. Individual cell clones
are designated by colored symbols. Below the red line, we show the
population of Vγ9Vδ2 T cells that do not respond to phosphoantigen (PAg)
and remain at roughly equal numbers irrespective of infection or treatment.
Without ART, HIV infection drives down the number and TCR complexity of
PAg-responsive Vγ9Vδ2 (above the red line). After prolonged ART, TCR
complexity recovers in the PAg-responding population (indicated by
different colors) but the numbers and functions remain below uninfected
controls. Adapted from Ref. (50, 70, 74).
with CD4< 200 cells/mm3 had no detectable Vγ9JP cells in PBMC
(14). When these patients initiated combination antiretroviral
therapy and achieved virus suppression, we did not observe rapid
rebound of Vδ2 cells in blood despite increases in CD4 cell count
during 2–2.5 years of treatment. The lack of rapid Vδ2 cell recov-
ery argues against the idea that depletion in peripheral blood is
due to increased tissue compartmentalization, which is an impor-
tant mechanism for controlling CD4 T cell count early in disease
(69). A subsequent study of patients with longer intervals of
antiretroviral therapy provided some initial evidence that Vγ9JP
cells were reconstituted during virus suppression but the recov-
ery rates were slow (13). More recently, studies with patients after
>7 years of antiretroviral therapy revealed extensive reconstitution
of the TCR cell repertoire (based on Vγ9 chain sequencing) and
a population of Vγ9JP chains having nearly the complexity found
in healthy, HIV-negative controls. Considering that some of the
treated patients had nadir CD4 counts below 100 cells/mm3 and
were expected to have no circulating Vγ9JP cells, reconstitution of
this population was a surprising result (70).
The γδ T cell repertoire is defined by analyzing the num-
ber and frequency of clonotypes (predicted peptide sequences
in the CDR3 or V-J region of the gamma chain) or nucleo-
types (nucleotide sequences for these peptides) within a sample
of the total population of TCR sequences in a blood or tis-
sue specimen. These sequences are classified as public (identical
amino acid sequences present in unrelated donors) or private
(unique to one individual in our population of donors). For
healthy, HIV-negative adults most of the clonotypes are public
and many of the nucleotypes are also public indicating a high
degree of similarity among unrelated individuals. This pattern
is consistent with the use of monomorphic antigen-presenting
molecules and is probably biased by nucleotide sequences in the
germline regions of Vγ9 and JP that provide alternate routes to
expressing the “germline” Vγ9JP rearrangement (70) using the
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mechanism of convergent recombination (71–73). In long-term
treated HIV patients, there were clear differences between unin-
fected controls or treated patients who reconstituted the Vγ9
repertoire as measured by clonotype and nucleotype abundance
(70). These differences prove that the repertoire was reconstituted
by new cell synthesis and not by regrowth of a cell population
that survived an initial HIV attack. Further, the reconstituted TCR
repertoire included many sequences that should respond to phos-
phoantigen. Despite having a reconstituted repertoire and TCR
against phosphoantigen, Vδ2 cells in these patients remained at
levels well below matched, HIV-negative controls and had greater
proportions of naïve cells indicating a lack of phosphoantigen
responses and impaired positive selection in vivo. Patients also
had lower expression of the CD56 cell surface marker (74) that is
associated with cytotoxic effector function (75). Vδ2 cells from
these long-term treated patients could be activated by potent
in vitro stimulation whereupon they regained Fc receptor expres-
sion (CD16) and effector function in antibody-dependent cellular
cytotoxicity (50). Despite reconstitution of the Vδ2 T cell pop-
ulation by new cell synthesis during prolonged ART, this subset
does not recover to normal levels or function after treatment
intervals of years to decades. The majority of Vδ2 cells found in
treated HIV patients were generated and selected in an environ-
ment almost devoid of HIV due to effective therapy. The nature
of this long-term defect is an obstacle to immune reconstitu-
tion and might contribute to chronic comorbid diseases in HIV
patients.
A very small fraction of HIV patients actually have normal Vδ2
cell levels and function; these are elite controllers or natural virus
suppressors defined as HIV patients with undetectable viremia
except for occasional blips and no history of antiretroviral ther-
apy (76). Among natural virus suppressor patients (approximately
0.5% of all persons with HIV infection), Vδ2 cell levels are equiv-
alent to age, gender, and race-matched uninfected controls but
there are significant differences in the Vγ9 chain repertoire (77).
These repertoire differences reflect an early impact of HIV before
the time when virus replication was controlled by host immunity
and in this way, are similar to what we observed in treated patients
where viremia was suppressed by chemotherapy. This also tells us
that normal function of Vγ9Vδ2 T cells can return in HIV-infected
patients but as yet, we have not uncovered the critical mecha-
nisms for recovery that might help us to find new therapeutic
targets.
MILESTONE ACHIEVEMENTS FROM THE MIDDLE PERIOD OF
STUDYING γδ T CELLS IN HIV DISEASE
Nearly three decades of research produced many insights into
HIV and γδ T cells. Studying HIV disease proved that Vγ9JPVδ2
cell depletion explained the defective response to phosphoanti-
gen. Mechanisms were described for specific loss of Vγ9JPVδ2
cells that account for the relationship between depletion and
phosphoantigen responsiveness. The findings showing that ther-
apy reconstituted the Vγ9 repertoire but did not restore normal
cell counts or function, were both encouraging and cautionary.
Changes in γδ T cells are clearly related to HIV immune evasion
but the long-term defects pose substantial challenges to the clinical
management of HIV and efforts to reduce comorbid diseases.
PROBLEM OF DURABLE γδ T CELL DAMAGE DESPITE
CHEMOTHERAPEUTIC SUPPRESSION OF HIV
Natural history studies of HIV infection documented a brief, vio-
lent interval of acute infection characterized by extraordinarily
high viremia and dramatic changes in immune cell populations,
which continued until a stable viral set-point (78) was established.
We prefer the term “immune set-point” that better describes the
balance between immune system destruction and chronic infec-
tion that allows HIV to persist in an individual or in the human
population. The immune set-point includes damage to Vδ2 T cell
function that goes beyond what is seen in acute, adult malaria
(79) for example, where there was a more limited transient loss of
Vγ9Vδ2 T cells.
Both viral and immunological set-points designate the phase
of disease when acute HIV infection gives way to a stable, per-
sistent infection with slower progression and more time for virus
to spread by sexual contact. In some virus examples, the acute to
persistent transition reflects changes in viral gene regulation but
in HIV disease the most important mechanisms are viral evasion
of host immunity. Once persistence is established, chronic dis-
ease progression causes death around 11 years later in untreated
HIV disease, as declining CD4 T cell counts and collapsing innate
immunity increase the incidence and severity of lethal opportunis-
tic infections, cancer, cardiovascular disease, and other terminal
conditions. Evolutionary selection of HIV created a pathogen
capable of spreading in the human population by relatively inef-
ficient sexual transmission even when the median life expectancy
after infection was only 11 years for adults and shorter for infected
infants or elderly persons. Now, in the era of effective ART and
much longer survival times, we are seeing a new scenario that was
not part of the selection pressures driving natural evolution of
HIV. Therapy with effective virus suppression repairs some of the
earlier immune damage and likely reduces transmission rates (80)
but key cell types including γδ T cells fail to recover normal num-
bers, phenotypes, or function, even after prolonged treatment that
also fails to eradicate the virus. These enduring defects and their
impacts on durable virus persistence or comorbidities of HIV are
unanticipated – or better said – unselected consequences of HIV
biology that are continuing decades after a viral immune eva-
sion mechanism that caused damage to host immunity during the
interval of acute infection.
Why these defects linger is a critical and unsolved question. We
know that low numbers of viral RNA remain in plasma even during
successful antiretroviral therapy (81) but these levels are around
105 vRNA copies per ml of plasma lower that what is found during
acute viremia. Accordingly, when the γ chain repertoire is recon-
stituted by new cell synthesis (70), we are dealing with cells that
were birthed in an environment nearly devoid of HIV replication.
Reconstitution is indeed slow as was predicted several years ago
(13), but the return of function lags behind the gain of TCR reper-
toire complexity and as of now, there is no reliable estimate for the
kinetics of functional recovery.
The durable impact of HIV on γδ T cells impedes their con-
tributions to key immune effector and regulatory mechanisms.
Relating the list of possible γδ T cell functions to the known out-
comes of HIV disease is a challenging undertaking and will trigger
much debate. Our list of relevant Vδ2 T cell functions (Figure 3)
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FIGURE 3 | Some of the known functions for humanVδ2T cells that are
related to HIV infection. Naïve Vδ2 T cells can be stimulated to produce
Type 1 cytokines/chemokines for antiviral immunity (47) or display potent
lytic effect function against tumor cells (82, 83) or infected cells (47). Vδ2 T
cells also provide and receive costimulation from both NK cells (86) and
dendritic cells (87). They display some similarity to T follicular helper cells
required for B cell responses (85) and can function as antigen-presenting
cells (84).
includes control of antiviral immunity (47), tumor or infected cell
killing (82, 83), antigen presentation (84), B helper T cell function
(85), and costimulation of NK cells (86, 87) although alternate
lists with additional functions can be imagined. In this review, we
focus on the impact of losing Vδ2 T cell costimulation and why
this loss can be an important underlying factor in HIV-associated
comorbid diseases that are causing death and disability in persons
despite effective viral suppression by ART.
The consequences of prolonged depression in Vδ2 T cell func-
tion may appear in unexpected comorbidities of HIV disease. For
example, psoriasis affects 1–3% of patients with HIV (88), which
seems paradoxical since this is a T cell-mediated autoimmune dis-
order (89). Normally, psoriasis is associated with influx of blood
Vγ9Vδ2 T cells into the inflamed skin that may be a mechanism for
resolving the acute condition. In HIV disease, we can imagine that
the absence of Vγ9Vδ2 T cells or their chronically poor responses
in patients treated with antiretroviral therapy will reduce their
beneficial effect and increase the severity or duration of psoriasis
in these patients. The Vγ9Vδ2 T cells are intimately related to both
NK and dendritic cells through interactions that control cell acti-
vation and inflammation. Psoriasis is an example where the loss
of Vγ9Vδ2 function removes a key protective mechanism.
Cell:cell interactions (cross-talk) involving γδ T cells were
implicated in the activation of dendritic cells (90), enhancement
of antibody production by γδ T cells with T follicular helper cell
activity (85) and antigen presentation or cross presentation (84).
An additional and more specific example of cross-talk involved
NK tumor cytotoxicity, which was activated by Vδ2 T cells (86).
The critical role for Vδ2 T cells in NK tumor cytotoxicity was
mapped to expression of the 4-1BB ligand (CD137L). Phospho-
antigen stimulation of human PBMC expanded the Vδ2 subset
and upregulated both 4-1BB (costimulatory receptor) and NKG2D
(activating receptor that recognizes stressed-self antigens) on the
NK cells (Figure 4). A murine cell line expressing 4-1BBL could be
substituted for Vδ2+ T cells indicating that this costimulatory lig-
and was the major signal for Vδ2 T cell enhancement of NK tumor
cytotoxicity (86). This surprising result linked the anti-tumor
effector activity of NK cells to the presence of phosphoantigens
and activation of Vδ2 T cells.
A second example of Vδ2 T cell costimulation of NK is
enhancement of effector activity capable of eliminating immature
or mature, antigen-presenting dendritic cells (Figure 5). Again,
phosphoantigen-expanded Vδ2 T cells delivered a costimulatory
signal to NK that increased the killing of autologous dendritic
cells. Along with increased production of Type 1 cytokines and
chemokines, the increased levels of ICOS on Vδ2 T cells binding
to ICOSL on NK cells was related to improving cytotoxic killing
of dendritic cells (87). The Vδ2 T cells are reciprocally activated by
the cross-talk with NK and may also be effectors for dendritic cell
killing, but these experiments are complicated by the use of anti-
TCR or anti-CD3 antibodies to purify Vδ2 cells. When antibodies
are used for positive selection, Vδ2 T cells are super-activated and
the effects of costimulation are obscured. These studies on costim-
ulation support an earlier model for NK:γδ:DC interactions that
focused on γδ T cell cytokines that regulate NK and DC function
(91). In this example, we see a key role for antigen-specific Vδ2
T cells in costimulation of NK cells that will then gain the capac-
ity for killing activated dendritic cells and help to control chronic
inflammation.
When Vδ2 T cell costimulation of NK cells is lost we might
expect increased cancer risk among HIV patients, despite effective
viral suppression by therapy. In HIV clinics of the University of
Maryland, Baltimore, more than 15% of all HIV patients will have
a cancer diagnosis and in 85% of those cases, cancer will be the
cause of death (92). The great variety of cancers that increase in
HIV patients suggests that a common mechanism of tumor con-
trol is missing or ineffective. Decreased tumor surveillance by NK
cells may contribute to this comorbidity of HIV-associated cancer
and the loss of Vδ2 T cell costimulation could be a key mechanism
for the loss of effector function.
Vδ2 T cell depletion, loss of costimulation, and the consequent
reduction in dendritic cell killing may have important effects on
several HIV-associated comorbidities. Chronic immune activa-
tion with inflammation is a hallmark of HIV disease and a danger
to patients even after virus replication is suppressed. The linger-
ing defect in Vδ2 T cells and the linked failure to co-stimulate
NK for dendritic cell killing, likely increases the risk for chronic
activation/inflammation as potent antigen-presenting cells accu-
mulate in the absence of normal control mechanisms. Indeed,
Fauci’s group noted the lack of potent dendritic cell editing by NK
in HIV-infected and treated patients (93) and defects in plasma-
cytoid dendritic cell–NK cross-talk in HIV patient specimens that
reflected poor activation of NK during innate immune responses
(94). Vδ2 T cells are also involved in reciprocal interactions with
dendritic cells that affect activation or maturation of both cell
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FIGURE 4 | Stimulated Vδ2T cells co-stimulate NK to increase tumor cell
cytolysis. Activated Vδ2 T cells express 4-1BBL that binds 4-1BB on NK cells.
The NKG2D receptor on NK is upregulated allowing stronger recognition of
tumor cells expressing self-stress ligands ULBP or MIC A/B (86).
HIV-mediated destruction of Vδ2 T cells will cripple the important mechanism
for NK costimulation and reduce natural tumor surveillance.
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FIGURE 5 | Vδ2 costimulation of NK cells increases lytic effector
activity against autologous dendritic cells. The Vδ2 and NK cells interact
through ICOS/ICOSL interactions resulting in upregulation of cytokine
expression, increased mRNA for several other costimulatory receptors and
increase lytic effector activity against dendritic cells (87). The relevant
receptor(s) on NK and recognition molecules on dendritic cells have not
been identified. Similar to the example in Figure 4, HIV-mediated depletion
of Vδ2 is expected to reduce the capacity for NK killing of dendritic cells
that will accumulate and promote chronic immune activation/inflammation
that is a hallmark of HIV disease.
types (90). Consequently, dysfunction of Vδ2 cells will affect NK
and dendritic cell interactions as all three cell types are interde-
pendent. When all three cell types are normal, there is a balance
between cell activation and cell killing that modulates inflamma-
tion. When one piece is missing, in this case Vδ2 T cells, the control
over inflammation is lost.
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The examples for defective Vδ2 T cells in HIV-infected and
treated patients have important parallels in the NK literature.
There are many reports about the phenotype of circulating NK
cells in patients where HIV is controlled by antiretroviral ther-
apy. In these patients, NK have lower density of NKp46, NKp30,
and NKp44 receptors (95) and often appear as CD56−/CD16+
cells lacking cytotoxic effector activity (96). Because HIV infection
is associated with decreased NKG2D (activating) and increased
NKG2A (inhibiting) receptor expression (97), even the increased
levels of ULBP target ligands failed to trigger cytolysis of HIV-
infected target cells. The earliest mark of NK dysfunction seems
to be the decreased expression of Siglec-7 (98). When the lack
of Siglec-7 is combined with lower expression of CD56 (99), we
are beginning to define the phenotype of defective NK cells that
is common among HIV patients. Whether these defects could be
corrected by costimulation has not yet been tested. Clearly, there is
a convergence of functional defects among Vδ2, NK, and dendritic
cells in HIV and potent antiretroviral therapy does not restore
the normal cell interactions or function of this regulatory trian-
gle. It is worthwhile to look for defects in multiple mechanisms of
immunity including those highlighted in Figure 3.
With highly effective antiretroviral therapy and increasing
interest in eradicating HIV, it is important to look at the future
of research on γδ T cells. Surely, Vδ2 T cells provide an attractive
target for immunotherapy, probably using aminobisphosphonate
compounds plus IL-2 or IL-15 to increase cell levels and func-
tions. Patterned on a number of ongoing clinical studies in cancer
(100–105), aminobisphosphonate drugs may be useful for cor-
recting the HIV-associated Vδ2 T cell defect. A pilot study showed
this approach was safe for HIV patients (106) but these stud-
ies have not been repeated or expanded to include clinical and
immunological endpoints such as NK or dendritic cell phenotype
and function. The lack of progress may be due to insufficient
justification for the outcome of bisphosphonate/IL-2 therapy,
since viremia can be suppressed more easily with once-a-day
antiretroviral agents.
PLEA FOR INNOVATIVE CLINICAL TRIALS TARGETING γδ T
CELLS IN HIV DISEASE
Clinical research on therapeutic restoration of γδ T cells in HIV
disease will require innovative clinical trial strategies. It may be
difficult to launch therapeutic interventions such as aminobis-
phosphonate plus IL-2 for 2 or 3 months, then wait 20 years or
more to accumulate significant data on changing rates of pul-
monary arterial hypertension (found in <5% of HIV patients)
or other comorbidities. While each of the comorbid conditions
affects only a portion of the HIV population, their combined
impact is substantial but clinical trials rarely lump disparate con-
ditions into single endpoints. We might overcome this problem by
using immunological endpoints that are related to chronic disease
mechanisms. For example, direct immunotherapy targeting γδ T
cells might be tested as a way to activate Vδ2 T cells that would
normalize NK cell phenotype and function. Recovering of normal
properties in two distinct lymphocyte subsets may be sufficient to
document a clinical benefit, even though neither change is likely
to result in short term changes to the incidence, prevalence, or
severity of comorbid diseases.
SUMMARY
The Vγ9Vδ2 T cells in HIV-infected individuals contain the his-
torical record of disease, documenting the intensity of initial
depletion and reconstitution during therapy by their abundance,
activity, and sequences of their TCR. They are barometers for
current disease status, reflecting the capacity for resisting oppor-
tunistic infections, natural tumor surveillance, the control of
immune activation/inflammation, and likely several other con-
ditions critical to the clinical management of HIV disease. In
addition, reconstitution of the TCR repertoire may be a mea-
sure for treatment success and help to identify patients with the
highest potential response to immunotherapies targeted at Vδ2 T
cell activation. Their compact TCR repertoire and extraordinar-
ily high proportion of public Vγ9 chains facilitates comparisons
among individuals or groups of patients. When combined with
the sophisticated knowledge about cell surface marker expression
including costimulatory receptors/ligands, and their patterns of
cytokine/chemokine expression, these cells become critical tools
for the immunology of infectious diseases. Adding to the inter-
est is the availability of approved drugs that activate Vγ9Vδ2 T
cells in vivo with high specificity, and a rich pipeline of com-
pounds under development that may do even better. The missing
link is a commitment to small interventional clinical trials testing
the capacity for γδ T cell-targeted immunotherapies to alter the
profile of immunity and recover normal control in diseases like
HIV/AIDS.
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